# to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection

> **NCT06437951** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 40 (estimated)

## Conditions studied

- Erosive Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Fexuprazan Injection
- **DRUG:** Fexuprazan Injection placebo
- **DRUG:** Fexuprazan Injection_part 2
- **DRUG:** Fexuprazan Injection_part 3
- **DRUG:** Fexuprazan tablet

## Key facts

- **NCT ID:** NCT06437951
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07
- **Primary completion:** 2025-01
- **Final completion:** 2025-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06437951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06437951, "to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06437951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*